直接抗病毒药物对HCV相关肝细胞癌根治性治疗后复发影响的Meta分析

刘宇维; 金晶兰; 任天羿; 高修竹; 李杰; 朱倩; 牛俊奇

doi:10.3969/j.issn.1001-5256.2020.12.015

直接抗病毒药物对HCV相关肝细胞癌根治性治疗后复发影响的Meta分析

DOI: 10.3969/j.issn.1001-5256.2020.12.015

吉林大学第一医院肝胆胰内科

基金项目:

国家自然科学基金（81970519）；

详细信息

中图分类号: R735.7
计量
- 文章访问数: 4392
- HTML全文浏览量: 20
- PDF下载量: 90
- 被引次数: 0
出版历程
- 收稿日期: 2020-06-18
- 出版日期: 2020-12-20

Effect of direct-acting antiviral on the recurrence hepatitis C virus-related hepatocellular carcinoma after curative treatment: A Meta-analysis

Department of Hepatology,The First Hospital of Jilin University

Research funding:

摘要

摘要:
目的评价直接抗病毒药物（DAA）对HCV相关肝细胞癌（HCC）根治性治疗后复发的影响。方法计算机检索PubMed、Web of Science、Cochrane Library、中国知网、中国生物医学数据库、万方数据库、维普数据库中有关DAA与HCV相关HCC复发的临床研究,检索时间为自数据库创立至2020年4月。采用Stata 14. 0软件进行Meta分析。各研究间异质性采用Cochran Q检验,非异质性数据采用固定效应模型,异质性数据采用随机效应模型。采用Egger回归法或Begg秩相关法检验是否存在发表偏倚。结果共纳入10篇文献,11项研究。其中有8篇文献,9项研究比较了DAA与未行抗HCV治疗对根治性治疗后HCC复发的影响。DAA组共纳入991例患者,未治疗组共纳入808例患者,Meta分析结果显示,DAA类药物可降低根治性治疗后HCV感染者HCC的复发率（HR=0. 42,95%CI:0. 28～0. 36,P<0. 001）。有3篇文献比较了DAA与干扰素治疗丙型肝炎对于根治性治疗后HCC复发的影响,其中DAA组共纳入267例患者,干扰素组共纳入212例患者。M...
- 抗病毒药 /
- 肝炎病毒属 /
- 癌,肝细胞 /
- 复发 /
- Meta分析（主题）
Abstract:
Objective To investigate the effect of direct-acting antiviral( DAA) on the recurrence of hepatitis C virus( HCV)-related hepatocellular carcinoma( HCC) after curative treatment. Methods PubMed,Web of Science,Cochrane Library,CNKI,CBM,Wanfang Data,and VIP were searched for the clinical studies of DAA and the recurrence of HCV-related HCC published up to April 2020. Stata14. 0 software was used to perform the meta-analysis. The Cochran Q test was used to evaluate heterogeneity between studies; the fixed effects model was used for non-heterogeneous data,and the random effects model was used for heterogeneous data. The Egger regression method or the Begg rank correlation method was used to evaluate the presence or absence of publication bias. Results A total of 10 articles( 11 studies) were included in our study,among which 8 articles( 9 studies) compared the effect of DAA versus the absence of anti-HCV therapy on the recurrence of HCC after curative treatment. There were 991 patients in DAA group and 808 patients in untreated group. The results of the meta-analysis showed that DAA reduced the recurrence rate of HCC after curative treatment in patients with HCV infection( hazard ratio [HR]= 0. 42,95% confidence interval [CI]: 0. 28? 0. 36,P < 0. 001). Three articles compared the effect of DAA versus interferon for the treatment of hepatitis C on the recurrence of HCC after curative treatment,with 267 patients in DAA group and 212 in interferon group,and the results of the meta-analysis showed that DAA and interferon had a similar effect on the recurrence rate of HCV-related HCC( HR = 0. 85,95% CI: 0. 64-1. 15,P = 0. 298). Conclusion Both interferon and DAA can significantly reduce the recurrence risk of HCV-related HCC after curative treatment,with no significant difference between them.
- antiviral agents /
- hepacivirus /
- carcinoma,hepatocellular /
- recurrence /
- Meta-analysis as topic

HTML全文

参考文献(36)

[1] BRAY F,FERLAY J,SOERJOMATARAM I,et al. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2018,68(6):394-424.

[2] OMATA M,CHENG AL,KOKUDO N,et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma:A 2017 update[J]. Hepatol Int,2017,11(4):317-370.

[3] IRSHAD M,MANKOTIA DS,IRSHAD K. An insight into the diagnosis and pathogenesis of hepatitis C virus infection[J].World J Gastroenterol,2013,19(44):7896-7909.

[4] FELD JJ,JACOBSON IM,HZODE C,et al. Sofosbuvir and velpatasvir for HCV genotype 1,2,4,5,and 6 infection[J].N Engl J Med,2015,373(27):2599-2607.

[5] REIG M,MARIO Z,PERELLC,et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy[J]. J Hepatol,2016,65(4):719-726.

[6] ROBERT SB Jr. The possible association between DAA treatment for HCV infection and HCC recurrence[J]. Gastroenterol Hepatol(N Y),2016,12(12):776-779.

[7] CONTI F,BUONFIGLIOLI F,SCUTERI A,et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals[J]. J Hepatol,2016,65(4):727-733.

[8] WARZYSZYN'SKA K,JONAS M,WASIAK D,et al. Accelerated hepatocellular carcinoma recurrence rate after postoperative direct-acting antivirals treatment-preliminary report[J].Clin Exp Hepatol,2017,3(4):194-197.

[9] TORRES HA,VAUTHEY JN,ECONOMIDES MP,et al. Hepatocellular carcinoma recurrence after treatment with directacting antivirals:First,do no harm by withdrawing treatment[J]. J Hepatol,2016,65(4):862-864.

[10] ANRS collaborative study group on hepatocellular carcinoma(ANRS CO22 HEPATHER,CO12 Cir Vir and CO23 CUPILT cohorts). Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma:Data from three ANRS cohorts[J]. J Hepatol,2016,65(4):734-740.

[11] VIRLOGEUX V,PRADAT P,HARTIG-LAVIE K,et al. Direct-acting antiviral therapy decreases hepatocellular carcinoma recurrence rate in cirrhotic patients with chronic hepatitis C[J]. Liver Int,2017,37(8):1122-1127.

[12] IKEDA K,KAWAMURA Y,KOBAYASHI M,et al. Direct-acting antivirals decreased tumor recurrence after initial treatment of hepatitis C virus-related hepatocellular carcinoma[J]. Dig Dis Sci,2017,62(10):2932-2942.

[13] HUANG AC,MEHTA N,DODGE JL,et al. Direct-acting antivirals do not increase the risk of hepatocellular carcinoma recurrence after local-regional therapy or liver transplant waitlist dropout[J]. Hepatology,2018,68(2):449-461.

[14] CABIBBO G,CELSA C,CALVARUSO V,et al. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients[J]. J Hepatol,2019,71(2):265-273.

[15] CHI CT,CHEN CY,SU CW,et al. Direct-acting antivirals for patients with chronic hepatitis C and hepatocellular carcinoma in Taiwan[J]. J Microbiol Immunol Infect,2019.[Online ahead of print]

[16] NISHIBATAKE KINOSHITA M,MINAMI T,TATEISHI R,et al.Impact of direct-acting antivirals on early recurrence of HCV-related HCC:Comparison with interferon-based therapy[J]. J Hepatol,2019,70(1):78-86.

[17] IMAI K,TAKAI K,HANAI T,et al. Sustained virological response by direct-acting antivirals reduces the recurrence risk of hepatitis C-related hepatocellular carcinoma after curative treatment[J]. Mol Clin Oncol,2020,12(2):111-116.

[18] KUO YH,WANG JH,CHANG KC,et al. The influence of direct-acting antivirals in hepatitis C virus related hepatocellular carcinoma after curative treatment[J]. Invest New Drugs,2020,38(1):202-210.

[19] MIUMA S,MIYAMOTO J,TAURA N,et al. Influence of interferon-free direct-acting antiviral therapy on primary hepatocellular carcinoma recurrence:A landmark time analysis and time-dependent extended cox proportional hazards model analysis[J]. Intern Med,2020,59(7):901-907.

[20] CAMMC,CABIBBO G,CRAXA. Direct antiviral agents and risk for HCC early recurrence:Much ado about nothing[J]. J Hepatol,2016,65(4):861-862.

[21] BLANCO JR,RIVERO-JUREZ A. The risk of hepatocellular carcinoma after sustained virological response in patients treated with the new direct-acting antiviral drugs:Should we be worry about it?[J]. Expert Rev Anti Infect Ther,2016,14(11):993-996.

[22] YANO H,IEMURA A,HARAMAKI M,et al. Interferon alfa receptor expression and growth inhibition by interferon alfa in human liver cancer cell lines[J]. Hepatology,1999,29(6):1708-1717.

[23] NAKAMURA M,NAGANO H,SAKON M,et al. Role of the Fas/Fas L pathway in combination therapy with interferon-alpha and fluorouracil against hepatocellular carcinoma in vitro[J]. J Hepatol,2007,46(1):77-88.

[24] GEORGE PM,BADIGER R,ALAZAWI W,et al. Pharmacology and therapeutic potential of interferons[J]. Pharmacol Ther,2012,135(1):44-53.

[25] MIYAKE Y,TAKAKI A,IWASAKI Y,et al. Meta-analysis:Interferon-alpha prevents the recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma[J]. J Viral Hepat,2010,17(4):287-292.

[26] HSU YC,HO HJ,WU MS,et al. Postoperative peg-interferon plus ribavirin is associated with reduced recurrence of hepatitis C virus-related hepatocellular carcinoma[J]. Hepatology,2013,58(1):150-157.

[27] NAGAOKI Y,IMAMURA M,NISHIDA Y,et al. The impact of interferon-free direct-acting antivirals on clinical outcome after curative treatment for hepatitis C virus-associated hepatocellular carcinoma:Comparison with interferon-based therapy[J]. J Med Virol,2019,91(4):650-658.

[28] MINAMI T,TATEISHI R,NAKAGOMI R,et al. The impact of direct-acting antivirals on early tumor recurrence after radiofrequency ablation in hepatitis C-related hepatocellular carcinoma[J]. J Hepatol,2016,65(6):1272-1273.

[29] WAZIRY R,HAJARIZADEH B,GREBELY J,et al. Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy:A systematic review,meta-analyses,and meta-regression[J]. J Hepatol,2017,67(6):1204-1212.

[30] SPAAN M,van OORD G,KREEFFT K,et al. Immunological analysis during interferon-free therapy for chronic hepatitis C virus infection reveals modulation of the natural killer cell compartment[J]. J Infect Dis,2016,213(2):216-223.

[31] SERTI E,CHEPA-LOTREA X,KIM YJ,et al. Successful interferon-free therapy of chronic hepatitis C virus infection normalizes natural killer cell function[J]. Gastroenterology,2015,149(1):190-200.

[32] VILLANI R,FACCIORUSSO A,BELLANTI F,et al. DAAs rapidly reduce inflammation but increase serum VEGF level:A rationale for tumor risk during Anti-HCV treatment[J]. PLo S One,2016,11(12):e0167934.

[33] LLOVET JM,VILLANUEVA A. Liver cancer:Effect of HCV clearance with direct-acting antiviral agents on HCC[J]. Nat Rev Gastroenterol Hepatol,2016,13(10):561-562.

[34] SINGH S,NAUTIYAL A,LOKE YK. Oral direct-acting antivirals and the incidence or recurrence of hepatocellular carcinoma:A systematic review and meta-analysis[J]. Frontline Gastroenterol,2018,9(4):262-270.

[35] GRIFFITH AS,HAYASHI PH,BURKE LM,et al. Decreased hepatocellular carcinoma tumor burden with the achievement of hepatitis C virus sustained virologic response:Unlocking the potential of T-cell-mediated immunosurveillance[J]. J Hepatocell Carcinoma,2018,5:55-59.

[36] MARTIN B,HENNECKE N,LOHMANN V,et al. Restoration of HCV-specific CD8+T cell function by interferon-free therapy[J]. J Hepatol,2014,61(3):538-543.

施引文献

资源附件(0)

访问统计